CClinicalTrials.gg
CompletedNCT06841315Updated Mar 10, 2026

A Varegacestat Hepatic Impairment Study

A Phase 1 interventional study of varegacestat in Healthy Volunteer and Hepatic Impairment (HI), sponsored by Immunome, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Immunome, Inc. · Phase 1, Interventional, and Other

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 84 Years
Sex
All
01

Study summary

This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.

Read the detailed description

This is an open-label, single-dose, parallel study to evaluate the effects of varying degrees of impaired hepatic function on the PK, safety, and tolerability of varegacestat in adult participants.

The study will be conducted sequentially. The study will enroll participants with mild (Group 2) and moderate (Group 3) hepatic impairment (HI) and healthy participants with normal hepatic function (Group 1) at a 1:1 ratio. Matched healthy participants may match to more than one participant in the HI groups. Subsequently, if appropriate, the study will enroll participants with severe (Group 4) HI and healthy participants with normal hepatic function (Group 1), as needed, to provide 1:1 matches for Group 4. The decision to conduct Group 4 enrollment will be contingent upon the assessment of the feasibility, PK, and safety data from Groups 1-3.

02

Conditions studied

  • Healthy Volunteer
  • Hepatic Impairment (HI)
03

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (Healthy Participants):

  • Healthy, adult, male or female (of nonchildbearing potential only), 18 to 84 years of age, inclusive, at the screening visit. Participant will be matched by age (± 10 years) and sex to a participant with hepatic impairment (HI). Each healthy participant may be matched to more than 1 participant with HI, but cannot be matched to more than 1 participant within the same HI group.
  • Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, and ECGs as deemed by the PI or designee

Inclusion Criteria (Hepatic Impairment):

  • Healthy, apart from HI, adult male or female (of nonchildbearing potential only), 18 to 84 years of age, inclusive, at the screening visit.
  • Considered to have HI (of any etiology) that has been clinically stable (no acute episodes of illness due to deterioration in hepatic function) for at least 1 month prior to dosing per the PI and Sponsor and is likely to remain stable throughout the study. To be classified as having hepatic impairment with known medical history of liver disease (with or without a known history of alcohol abuse).
  • Has a score on the Child-Pugh scale at screening visit and confirmed at check-in as follows:

Mild: ≥5 and ≤6 [Category A]; or

Moderate: ≥7 and ≤9 [Category B]; or

Severe: ≥10 and ≤15 [Category C].

- Medically healthy, apart from HI, with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, and ECGs as deemed by the PI or designee

Exclusion Criteria (Healthy Volunteers):

  • Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  • History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
  • History of any illness that, in the opinion of the PI or designee, might confound the results of the study or pose an additional risk to the participant by their participation in the study.

Exclusion Criteria (Hepatic Impairment):

Participants must not be enrolled in the study, if they meet any of the following criteria:

  • Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  • History or presence of clinically significant medical (except for HI) or psychiatric condition or disease in the opinion of the PI or designee.
  • History of any illness that, in the opinion of the PI or designee, might confound the results of the study or pose an additional risk to the participant by their participation in the study.
04

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    Single oral dose of varegacestat administered on study day 1

    Drug: varegacestat

Interventions

  • Drugvaregacestat

    experimental intervention

05

What researchers measure

Primary outcomes

  1. PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.

    AUC0-t varegacestat and metabolite

    Time frame: Up to 4 weeks

  2. PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.

    AUC0-inf for varegacestat and metabolite

    Time frame: Up to 4 weeks

  3. PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.

    Cmax for varegacestat and metabolite

    Time frame: Up to 4 weeks

Secondary outcomes

  1. Assess the safety and tolerability of a single oral dose of varegacestat in hepatic impaired adult participants and in matched healthy adult participants.

    Number of subjects who experience treatment emergent adverse events (TEAEs)

    Time frame: Up to 4 weeks

  2. Assess the safety and tolerability of a single oral dose of varegacestat in hepatic impaired adult participants and in matched healthy adult participants.

    Number of subjects who experience abnormalities in vital signs and in clinical laboratory tests such as serum chemistry and hematology

    Time frame: Up to 4 weeks

  3. Assess the safety and tolerability of a single oral dose of varegacestat in hepatic impaired adult participants and in matched healthy adult participants.

    Number of subjects who experience 12-lead ECG abnormalities

    Time frame: Up to 4 weeks

06

Study locations

2 sites
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • The Texas Liver Institute
    San Antonio, Texas 78215, United States
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06841315
Lead sponsor
Immunome, Inc.
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Mar 7, 2025
Primary completion
Nov 5, 2025
Completion
Mar 6, 2026
Last update
Mar 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion